Denver, Feb. 13, 2018 (GLOBE NEWSWIRE) — TranS1®, a spinal device company focused on breakthrough solutions that minimize tissue trauma, today announced it has added three new patents to its portfolio. The patents relate to two new developments associated with presacral interbody fusion, including two new expandable cages designed to create lordosis at L5-S1, along with a new technique to perform sacroiliac (SI) fusion.
“TranS1’s patent portfolio remains one of the strongest in the industry,” said Jeffrey Schell, chief executive officer of TranS1, who is also a patent attorney. “Our strategy remains to advance the most innovative technologies to lessen tissue trauma during spine surgery and to vigorously guard those technological innovations through domestic and international patent protection.”
TranS1 offers a full complement of minimally invasive surgery (MIS) solutions for spinal pathologies, including the award-winning Pylon™ posterolateral decortication and bone graft placement system, the KeyLIF™ MIS Oblique Lateral Interbody Fusion system and the AxiaLIF® presacral interbody fusion system.The AxiaLIF procedure allows for minimally invasive spinal fusion at L5-S1 for patients with certain spinal pathologies. Presacral interbody fusion at L5-S1 was awarded a Category 1 CPT® Code (22586) in 2013 by the American Medical Association’s CPT Editorial Committee. According to the CPT Editorial Panel, procedures recognized as Category 1 are widely performed throughout the United States, consistent with accepted medical practice and supported by relevant published research demonstrating the clinical efficacy of the procedure.
In addition to its full suite of MIS procedures and devices, TranS1 has also created and continues to develop a patent portfolio focused on spinal health technologies. The company remains committed to becoming the most innovative in the industry by developing new technologies, applying lessons learned from its development of related approaches, and by attracting the most experienced engineers and surgeons to its team. In all, TranS1 has more than 100 issued patents and has filed more than 50 new patent applications in the last three years.
About TranS1
Headquartered in Denver, TranS1 develops medical breakthroughs to solve spinal pathologies that minimize trauma to the tissues surrounding the spine. The company’s flagship product, AxiaLIF+, is a minimally invasive option for surgeons to accomplish spinal fusion at the L5-S1 joint. The company was named Denver’s Most Innovative Workplace by the 80/95 Awards, presented by the Denver Post. In 2017, the company won the “New Spine Technology” award from Orthopedics This Week for its Pylon™ MIS Posterolateral Decortication and Bone Graft Placement System. For more information, visit www.TranS1.com.